BioCryst Celebrates Bob Ingram’s Contributions to the Company’s Success

·2 min read
BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc.

RESEARCH TRIANGLE PARK, N.C., March 29, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today acknowledged the many contributions of Robert A. Ingram, the company’s chairman of the board, who recently passed away.

We are very saddened by his loss and our thoughts and prayers go to Bob’s wife Jeanie and his sons Cameron, Michael and Rory.

Bob served as a board member since 2015 and chairman since 2017 and played a central role in recruiting highly accomplished board members who brought a wide diversity of skills. He set a tone of transparency with management that created a highly effective relationship that has led to some of the most productive years in the company’s history.
  
“Bob was a wonderful mentor to me and I am forever grateful to have had the time I did with him in helping build our company. I will miss him, but know that he has made us better. We will work to keep his spirit and influence alive to guide us as we continue to work hard to help patients around the world who are living with rare diseases,” said Jon Stonehouse, chief executive officer of BioCryst.

“Bob Ingram has directly affected millions of lives through his leadership, support and development of new medicines throughout his career. We are grateful for his leadership of our board, and the gracious wisdom he always shared with us,” said board member Dr. Nancy Hutson on behalf of the BioCryst board of directors.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO® (berotralstat) is approved in the United States and many global markets. BioCryst has active programs to develop oral medicines for multiple targets across the complement system, including BCX10013, an oral Factor D inhibitor in clinical development. RAPIVAB® (peramivir injection) is approved in the U.S. and multiple global markets, with post-marketing commitments ongoing. For more information, please visit the company’s website at www.biocryst.com.

BCRXW

Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com